Outcome and prognostic factors in patients with mantle-cell lymphoma relapsing after autologous stem-cell transplantation: a retrospective study of the European Group for Blood and Marrow Transplantation (EBMT)
Autologous stem-cell transplantation (autoSCT) is considered a standard treatment of non-frail patients with mantle cell lymphoma (MCL), but little is known about outcome of MCL patients relapsing after autoSCT. We therefore sought to analyse the outcome after autoSCT failure and the efficacy of a r...
Gespeichert in:
| Veröffentlicht in: | Annals of oncology 2014-05, Vol.25 (5), p.1053-1058 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1058 |
|---|---|
| container_issue | 5 |
| container_start_page | 1053 |
| container_title | Annals of oncology |
| container_volume | 25 |
| creator | Dietrich, S. Boumendil, A. Finel, H. Avivi, I. Volin, L. Cornelissen, J. Jarosinska, R.J. Schmid, C. Finke, J. Stevens, W.B.C. Schouten, H.C. Kaufmann, M. Sebban, C. Trneny, M. Kobbe, G. Fornecker, L.M. Schetelig, J. Kanfer, E. Heinicke, T. Pfreundschuh, M. Diez-Martin, J.L. Bordessoule, D. Robinson, S. Dreger, P. |
| description | Autologous stem-cell transplantation (autoSCT) is considered a standard treatment of non-frail patients with mantle cell lymphoma (MCL), but little is known about outcome of MCL patients relapsing after autoSCT. We therefore sought to analyse the outcome after autoSCT failure and the efficacy of a rescue stem-cell transplantation (SCT) in this setting.
Patients with MCL were eligible if they had relapsed after autoSCT performed between 2000 and 2009. A total of 1054 patients could be identified in the EBMT registry. By contacting the transplant centres, a full dataset could be retrieved for 360 patients.
Median overall survival (OS) after relapse of the whole study group was 19 months. A long (>12 months) interval between autoSCT and relapse [P < 0.001, hazard ratio (HR) 0.62], primary refractory disease (P < 0.02, HR 1.92), prior high-dose ARA-C treatment (P = 0.04, HR 1.43), and the year of relapse (P = 0.02, HR 0.92) significantly influenced OS from relapse in multivariate analysis.
Eighty patients (22%) received a rescue allogeneic SCT (alloSCT). Relapse incidence, non-relapse mortality, and OS 2 years after alloSCT was 33% [confidence interval (95% CI 21% to 45%)], 30% (95% CI 19% to 42%), and 46% (95% CI 33% to 59%), respectively. Remission duration after autoSCT was the only variable significantly affecting the outcome of salvage alloSCT. In contrast, rescue autoSCT was not associated with long-term disease control. However, individual patients survived long term even without salvage transplantation.
MCL recurrence within 1 year after autoSCT has an extremely dismal outcome, while the prognosis of patients with longer remission durations after autoSCT is significantly better. AlloSCT may offer the possibility of durable survival when performed for patients with a remission duration of more than 12 months after first autoSCT, but the favourable effect of a salvage alloSCT in this setting needs further validation. |
| doi_str_mv | 10.1093/annonc/mdu097 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1519836889</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/annonc/mdu097</oup_id><els_id>S092375341934788X</els_id><sourcerecordid>1519836889</sourcerecordid><originalsourceid>FETCH-LOGICAL-c443t-22354456c1dc706cd39b8066e330dd25b292969117e1604c05aab9ae1613871d3</originalsourceid><addsrcrecordid>eNqFkU9v1DAQxS0EoqVw5IrmglQOoXacf-ZGq6UgteplOUdee7Jr5NjBdlrt1-QT4SULFQfEyRrpN8_z3iPkNaPvGRX8QjrnnboY9UxF-4ScsroRRUcr9pScUlHyoq15dUJexPiNUtqIUjwnJ2VVd3XLxCn5cTcn5UcE6TRMwW-dj8koGKRKPkQwDiaZDLoU4cGkHYzSJYuFQmvB7sdp50cJAa2conFbkEPCAHJO3vqtnyPEhONCpyBdnGzez4LefYDDXgo-TqiSuceMznoPfoC0Q1jNwU8oHVwHP08w-ACX1nv969BbGYJ_gPXfinC-urxdv3tJng3SRnx1fM_I10-r9dXn4ubu-svVx5tCVRVPRVnyuqrqRjGtWtoozcWmo02DnFOty3pT5qwawViLrKGVorWUGyHzwHjXMs3PyPmim2P7PmNM_Wjiwal0mJ33rGai403XiYwWC6qy3Rhw6KdgRhn2PaP9ocZ-qbFfasz8m6P0vBlR_6F_95aBt0dARiXtkINQJj5yXVWWrWCPN-YM__tnu6CYM7s3GPqocu8KtQm5oF5784_NnwxYzjI</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1519836889</pqid></control><display><type>article</type><title>Outcome and prognostic factors in patients with mantle-cell lymphoma relapsing after autologous stem-cell transplantation: a retrospective study of the European Group for Blood and Marrow Transplantation (EBMT)</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Dietrich, S. ; Boumendil, A. ; Finel, H. ; Avivi, I. ; Volin, L. ; Cornelissen, J. ; Jarosinska, R.J. ; Schmid, C. ; Finke, J. ; Stevens, W.B.C. ; Schouten, H.C. ; Kaufmann, M. ; Sebban, C. ; Trneny, M. ; Kobbe, G. ; Fornecker, L.M. ; Schetelig, J. ; Kanfer, E. ; Heinicke, T. ; Pfreundschuh, M. ; Diez-Martin, J.L. ; Bordessoule, D. ; Robinson, S. ; Dreger, P.</creator><creatorcontrib>Dietrich, S. ; Boumendil, A. ; Finel, H. ; Avivi, I. ; Volin, L. ; Cornelissen, J. ; Jarosinska, R.J. ; Schmid, C. ; Finke, J. ; Stevens, W.B.C. ; Schouten, H.C. ; Kaufmann, M. ; Sebban, C. ; Trneny, M. ; Kobbe, G. ; Fornecker, L.M. ; Schetelig, J. ; Kanfer, E. ; Heinicke, T. ; Pfreundschuh, M. ; Diez-Martin, J.L. ; Bordessoule, D. ; Robinson, S. ; Dreger, P.</creatorcontrib><description>Autologous stem-cell transplantation (autoSCT) is considered a standard treatment of non-frail patients with mantle cell lymphoma (MCL), but little is known about outcome of MCL patients relapsing after autoSCT. We therefore sought to analyse the outcome after autoSCT failure and the efficacy of a rescue stem-cell transplantation (SCT) in this setting.
Patients with MCL were eligible if they had relapsed after autoSCT performed between 2000 and 2009. A total of 1054 patients could be identified in the EBMT registry. By contacting the transplant centres, a full dataset could be retrieved for 360 patients.
Median overall survival (OS) after relapse of the whole study group was 19 months. A long (>12 months) interval between autoSCT and relapse [P < 0.001, hazard ratio (HR) 0.62], primary refractory disease (P < 0.02, HR 1.92), prior high-dose ARA-C treatment (P = 0.04, HR 1.43), and the year of relapse (P = 0.02, HR 0.92) significantly influenced OS from relapse in multivariate analysis.
Eighty patients (22%) received a rescue allogeneic SCT (alloSCT). Relapse incidence, non-relapse mortality, and OS 2 years after alloSCT was 33% [confidence interval (95% CI 21% to 45%)], 30% (95% CI 19% to 42%), and 46% (95% CI 33% to 59%), respectively. Remission duration after autoSCT was the only variable significantly affecting the outcome of salvage alloSCT. In contrast, rescue autoSCT was not associated with long-term disease control. However, individual patients survived long term even without salvage transplantation.
MCL recurrence within 1 year after autoSCT has an extremely dismal outcome, while the prognosis of patients with longer remission durations after autoSCT is significantly better. AlloSCT may offer the possibility of durable survival when performed for patients with a remission duration of more than 12 months after first autoSCT, but the favourable effect of a salvage alloSCT in this setting needs further validation.</description><identifier>ISSN: 0923-7534</identifier><identifier>EISSN: 1569-8041</identifier><identifier>DOI: 10.1093/annonc/mdu097</identifier><identifier>PMID: 24585719</identifier><language>eng</language><publisher>Oxford: Elsevier Ltd</publisher><subject>Adult ; Aged ; allogeneic stem-cell transplantation ; Antineoplastic agents ; autologous stem-cell transplantation ; Biological and medical sciences ; Disease-Free Survival ; Female ; Hematologic and hematopoietic diseases ; Humans ; Kaplan-Meier Estimate ; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis ; Lymphoma, Mantle-Cell - mortality ; Lymphoma, Mantle-Cell - pathology ; Lymphoma, Mantle-Cell - therapy ; Male ; mantle cell lymphoma relapse ; Medical sciences ; Middle Aged ; Multivariate Analysis ; Neoplasm Recurrence, Local ; Pharmacology. Drug treatments ; Prognosis ; Proportional Hazards Models ; Retrospective Studies ; Salvage Therapy ; Stem Cell Transplantation ; Transplantation, Autologous ; Treatment Failure ; Treatment Outcome</subject><ispartof>Annals of oncology, 2014-05, Vol.25 (5), p.1053-1058</ispartof><rights>2014 European Society for Medical Oncology</rights><rights>The Author 2014. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com. 2014</rights><rights>2015 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c443t-22354456c1dc706cd39b8066e330dd25b292969117e1604c05aab9ae1613871d3</citedby><cites>FETCH-LOGICAL-c443t-22354456c1dc706cd39b8066e330dd25b292969117e1604c05aab9ae1613871d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=28422791$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24585719$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Dietrich, S.</creatorcontrib><creatorcontrib>Boumendil, A.</creatorcontrib><creatorcontrib>Finel, H.</creatorcontrib><creatorcontrib>Avivi, I.</creatorcontrib><creatorcontrib>Volin, L.</creatorcontrib><creatorcontrib>Cornelissen, J.</creatorcontrib><creatorcontrib>Jarosinska, R.J.</creatorcontrib><creatorcontrib>Schmid, C.</creatorcontrib><creatorcontrib>Finke, J.</creatorcontrib><creatorcontrib>Stevens, W.B.C.</creatorcontrib><creatorcontrib>Schouten, H.C.</creatorcontrib><creatorcontrib>Kaufmann, M.</creatorcontrib><creatorcontrib>Sebban, C.</creatorcontrib><creatorcontrib>Trneny, M.</creatorcontrib><creatorcontrib>Kobbe, G.</creatorcontrib><creatorcontrib>Fornecker, L.M.</creatorcontrib><creatorcontrib>Schetelig, J.</creatorcontrib><creatorcontrib>Kanfer, E.</creatorcontrib><creatorcontrib>Heinicke, T.</creatorcontrib><creatorcontrib>Pfreundschuh, M.</creatorcontrib><creatorcontrib>Diez-Martin, J.L.</creatorcontrib><creatorcontrib>Bordessoule, D.</creatorcontrib><creatorcontrib>Robinson, S.</creatorcontrib><creatorcontrib>Dreger, P.</creatorcontrib><title>Outcome and prognostic factors in patients with mantle-cell lymphoma relapsing after autologous stem-cell transplantation: a retrospective study of the European Group for Blood and Marrow Transplantation (EBMT)</title><title>Annals of oncology</title><addtitle>Ann Oncol</addtitle><description>Autologous stem-cell transplantation (autoSCT) is considered a standard treatment of non-frail patients with mantle cell lymphoma (MCL), but little is known about outcome of MCL patients relapsing after autoSCT. We therefore sought to analyse the outcome after autoSCT failure and the efficacy of a rescue stem-cell transplantation (SCT) in this setting.
Patients with MCL were eligible if they had relapsed after autoSCT performed between 2000 and 2009. A total of 1054 patients could be identified in the EBMT registry. By contacting the transplant centres, a full dataset could be retrieved for 360 patients.
Median overall survival (OS) after relapse of the whole study group was 19 months. A long (>12 months) interval between autoSCT and relapse [P < 0.001, hazard ratio (HR) 0.62], primary refractory disease (P < 0.02, HR 1.92), prior high-dose ARA-C treatment (P = 0.04, HR 1.43), and the year of relapse (P = 0.02, HR 0.92) significantly influenced OS from relapse in multivariate analysis.
Eighty patients (22%) received a rescue allogeneic SCT (alloSCT). Relapse incidence, non-relapse mortality, and OS 2 years after alloSCT was 33% [confidence interval (95% CI 21% to 45%)], 30% (95% CI 19% to 42%), and 46% (95% CI 33% to 59%), respectively. Remission duration after autoSCT was the only variable significantly affecting the outcome of salvage alloSCT. In contrast, rescue autoSCT was not associated with long-term disease control. However, individual patients survived long term even without salvage transplantation.
MCL recurrence within 1 year after autoSCT has an extremely dismal outcome, while the prognosis of patients with longer remission durations after autoSCT is significantly better. AlloSCT may offer the possibility of durable survival when performed for patients with a remission duration of more than 12 months after first autoSCT, but the favourable effect of a salvage alloSCT in this setting needs further validation.</description><subject>Adult</subject><subject>Aged</subject><subject>allogeneic stem-cell transplantation</subject><subject>Antineoplastic agents</subject><subject>autologous stem-cell transplantation</subject><subject>Biological and medical sciences</subject><subject>Disease-Free Survival</subject><subject>Female</subject><subject>Hematologic and hematopoietic diseases</subject><subject>Humans</subject><subject>Kaplan-Meier Estimate</subject><subject>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</subject><subject>Lymphoma, Mantle-Cell - mortality</subject><subject>Lymphoma, Mantle-Cell - pathology</subject><subject>Lymphoma, Mantle-Cell - therapy</subject><subject>Male</subject><subject>mantle cell lymphoma relapse</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Multivariate Analysis</subject><subject>Neoplasm Recurrence, Local</subject><subject>Pharmacology. Drug treatments</subject><subject>Prognosis</subject><subject>Proportional Hazards Models</subject><subject>Retrospective Studies</subject><subject>Salvage Therapy</subject><subject>Stem Cell Transplantation</subject><subject>Transplantation, Autologous</subject><subject>Treatment Failure</subject><subject>Treatment Outcome</subject><issn>0923-7534</issn><issn>1569-8041</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkU9v1DAQxS0EoqVw5IrmglQOoXacf-ZGq6UgteplOUdee7Jr5NjBdlrt1-QT4SULFQfEyRrpN8_z3iPkNaPvGRX8QjrnnboY9UxF-4ScsroRRUcr9pScUlHyoq15dUJexPiNUtqIUjwnJ2VVd3XLxCn5cTcn5UcE6TRMwW-dj8koGKRKPkQwDiaZDLoU4cGkHYzSJYuFQmvB7sdp50cJAa2conFbkEPCAHJO3vqtnyPEhONCpyBdnGzez4LefYDDXgo-TqiSuceMznoPfoC0Q1jNwU8oHVwHP08w-ACX1nv969BbGYJ_gPXfinC-urxdv3tJng3SRnx1fM_I10-r9dXn4ubu-svVx5tCVRVPRVnyuqrqRjGtWtoozcWmo02DnFOty3pT5qwawViLrKGVorWUGyHzwHjXMs3PyPmim2P7PmNM_Wjiwal0mJ33rGai403XiYwWC6qy3Rhw6KdgRhn2PaP9ocZ-qbFfasz8m6P0vBlR_6F_95aBt0dARiXtkINQJj5yXVWWrWCPN-YM__tnu6CYM7s3GPqocu8KtQm5oF5784_NnwxYzjI</recordid><startdate>20140501</startdate><enddate>20140501</enddate><creator>Dietrich, S.</creator><creator>Boumendil, A.</creator><creator>Finel, H.</creator><creator>Avivi, I.</creator><creator>Volin, L.</creator><creator>Cornelissen, J.</creator><creator>Jarosinska, R.J.</creator><creator>Schmid, C.</creator><creator>Finke, J.</creator><creator>Stevens, W.B.C.</creator><creator>Schouten, H.C.</creator><creator>Kaufmann, M.</creator><creator>Sebban, C.</creator><creator>Trneny, M.</creator><creator>Kobbe, G.</creator><creator>Fornecker, L.M.</creator><creator>Schetelig, J.</creator><creator>Kanfer, E.</creator><creator>Heinicke, T.</creator><creator>Pfreundschuh, M.</creator><creator>Diez-Martin, J.L.</creator><creator>Bordessoule, D.</creator><creator>Robinson, S.</creator><creator>Dreger, P.</creator><general>Elsevier Ltd</general><general>Oxford University Press</general><scope>6I.</scope><scope>AAFTH</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20140501</creationdate><title>Outcome and prognostic factors in patients with mantle-cell lymphoma relapsing after autologous stem-cell transplantation: a retrospective study of the European Group for Blood and Marrow Transplantation (EBMT)</title><author>Dietrich, S. ; Boumendil, A. ; Finel, H. ; Avivi, I. ; Volin, L. ; Cornelissen, J. ; Jarosinska, R.J. ; Schmid, C. ; Finke, J. ; Stevens, W.B.C. ; Schouten, H.C. ; Kaufmann, M. ; Sebban, C. ; Trneny, M. ; Kobbe, G. ; Fornecker, L.M. ; Schetelig, J. ; Kanfer, E. ; Heinicke, T. ; Pfreundschuh, M. ; Diez-Martin, J.L. ; Bordessoule, D. ; Robinson, S. ; Dreger, P.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c443t-22354456c1dc706cd39b8066e330dd25b292969117e1604c05aab9ae1613871d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Adult</topic><topic>Aged</topic><topic>allogeneic stem-cell transplantation</topic><topic>Antineoplastic agents</topic><topic>autologous stem-cell transplantation</topic><topic>Biological and medical sciences</topic><topic>Disease-Free Survival</topic><topic>Female</topic><topic>Hematologic and hematopoietic diseases</topic><topic>Humans</topic><topic>Kaplan-Meier Estimate</topic><topic>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</topic><topic>Lymphoma, Mantle-Cell - mortality</topic><topic>Lymphoma, Mantle-Cell - pathology</topic><topic>Lymphoma, Mantle-Cell - therapy</topic><topic>Male</topic><topic>mantle cell lymphoma relapse</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Multivariate Analysis</topic><topic>Neoplasm Recurrence, Local</topic><topic>Pharmacology. Drug treatments</topic><topic>Prognosis</topic><topic>Proportional Hazards Models</topic><topic>Retrospective Studies</topic><topic>Salvage Therapy</topic><topic>Stem Cell Transplantation</topic><topic>Transplantation, Autologous</topic><topic>Treatment Failure</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Dietrich, S.</creatorcontrib><creatorcontrib>Boumendil, A.</creatorcontrib><creatorcontrib>Finel, H.</creatorcontrib><creatorcontrib>Avivi, I.</creatorcontrib><creatorcontrib>Volin, L.</creatorcontrib><creatorcontrib>Cornelissen, J.</creatorcontrib><creatorcontrib>Jarosinska, R.J.</creatorcontrib><creatorcontrib>Schmid, C.</creatorcontrib><creatorcontrib>Finke, J.</creatorcontrib><creatorcontrib>Stevens, W.B.C.</creatorcontrib><creatorcontrib>Schouten, H.C.</creatorcontrib><creatorcontrib>Kaufmann, M.</creatorcontrib><creatorcontrib>Sebban, C.</creatorcontrib><creatorcontrib>Trneny, M.</creatorcontrib><creatorcontrib>Kobbe, G.</creatorcontrib><creatorcontrib>Fornecker, L.M.</creatorcontrib><creatorcontrib>Schetelig, J.</creatorcontrib><creatorcontrib>Kanfer, E.</creatorcontrib><creatorcontrib>Heinicke, T.</creatorcontrib><creatorcontrib>Pfreundschuh, M.</creatorcontrib><creatorcontrib>Diez-Martin, J.L.</creatorcontrib><creatorcontrib>Bordessoule, D.</creatorcontrib><creatorcontrib>Robinson, S.</creatorcontrib><creatorcontrib>Dreger, P.</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Annals of oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Dietrich, S.</au><au>Boumendil, A.</au><au>Finel, H.</au><au>Avivi, I.</au><au>Volin, L.</au><au>Cornelissen, J.</au><au>Jarosinska, R.J.</au><au>Schmid, C.</au><au>Finke, J.</au><au>Stevens, W.B.C.</au><au>Schouten, H.C.</au><au>Kaufmann, M.</au><au>Sebban, C.</au><au>Trneny, M.</au><au>Kobbe, G.</au><au>Fornecker, L.M.</au><au>Schetelig, J.</au><au>Kanfer, E.</au><au>Heinicke, T.</au><au>Pfreundschuh, M.</au><au>Diez-Martin, J.L.</au><au>Bordessoule, D.</au><au>Robinson, S.</au><au>Dreger, P.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Outcome and prognostic factors in patients with mantle-cell lymphoma relapsing after autologous stem-cell transplantation: a retrospective study of the European Group for Blood and Marrow Transplantation (EBMT)</atitle><jtitle>Annals of oncology</jtitle><addtitle>Ann Oncol</addtitle><date>2014-05-01</date><risdate>2014</risdate><volume>25</volume><issue>5</issue><spage>1053</spage><epage>1058</epage><pages>1053-1058</pages><issn>0923-7534</issn><eissn>1569-8041</eissn><abstract>Autologous stem-cell transplantation (autoSCT) is considered a standard treatment of non-frail patients with mantle cell lymphoma (MCL), but little is known about outcome of MCL patients relapsing after autoSCT. We therefore sought to analyse the outcome after autoSCT failure and the efficacy of a rescue stem-cell transplantation (SCT) in this setting.
Patients with MCL were eligible if they had relapsed after autoSCT performed between 2000 and 2009. A total of 1054 patients could be identified in the EBMT registry. By contacting the transplant centres, a full dataset could be retrieved for 360 patients.
Median overall survival (OS) after relapse of the whole study group was 19 months. A long (>12 months) interval between autoSCT and relapse [P < 0.001, hazard ratio (HR) 0.62], primary refractory disease (P < 0.02, HR 1.92), prior high-dose ARA-C treatment (P = 0.04, HR 1.43), and the year of relapse (P = 0.02, HR 0.92) significantly influenced OS from relapse in multivariate analysis.
Eighty patients (22%) received a rescue allogeneic SCT (alloSCT). Relapse incidence, non-relapse mortality, and OS 2 years after alloSCT was 33% [confidence interval (95% CI 21% to 45%)], 30% (95% CI 19% to 42%), and 46% (95% CI 33% to 59%), respectively. Remission duration after autoSCT was the only variable significantly affecting the outcome of salvage alloSCT. In contrast, rescue autoSCT was not associated with long-term disease control. However, individual patients survived long term even without salvage transplantation.
MCL recurrence within 1 year after autoSCT has an extremely dismal outcome, while the prognosis of patients with longer remission durations after autoSCT is significantly better. AlloSCT may offer the possibility of durable survival when performed for patients with a remission duration of more than 12 months after first autoSCT, but the favourable effect of a salvage alloSCT in this setting needs further validation.</abstract><cop>Oxford</cop><pub>Elsevier Ltd</pub><pmid>24585719</pmid><doi>10.1093/annonc/mdu097</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0923-7534 |
| ispartof | Annals of oncology, 2014-05, Vol.25 (5), p.1053-1058 |
| issn | 0923-7534 1569-8041 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1519836889 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
| subjects | Adult Aged allogeneic stem-cell transplantation Antineoplastic agents autologous stem-cell transplantation Biological and medical sciences Disease-Free Survival Female Hematologic and hematopoietic diseases Humans Kaplan-Meier Estimate Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis Lymphoma, Mantle-Cell - mortality Lymphoma, Mantle-Cell - pathology Lymphoma, Mantle-Cell - therapy Male mantle cell lymphoma relapse Medical sciences Middle Aged Multivariate Analysis Neoplasm Recurrence, Local Pharmacology. Drug treatments Prognosis Proportional Hazards Models Retrospective Studies Salvage Therapy Stem Cell Transplantation Transplantation, Autologous Treatment Failure Treatment Outcome |
| title | Outcome and prognostic factors in patients with mantle-cell lymphoma relapsing after autologous stem-cell transplantation: a retrospective study of the European Group for Blood and Marrow Transplantation (EBMT) |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T02%3A33%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Outcome%20and%20prognostic%20factors%20in%20patients%20with%20mantle-cell%20lymphoma%20relapsing%20after%20autologous%20stem-cell%20transplantation:%20a%20retrospective%20study%20of%20the%20European%20Group%20for%20Blood%20and%20Marrow%20Transplantation%20(EBMT)&rft.jtitle=Annals%20of%20oncology&rft.au=Dietrich,%20S.&rft.date=2014-05-01&rft.volume=25&rft.issue=5&rft.spage=1053&rft.epage=1058&rft.pages=1053-1058&rft.issn=0923-7534&rft.eissn=1569-8041&rft_id=info:doi/10.1093/annonc/mdu097&rft_dat=%3Cproquest_cross%3E1519836889%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1519836889&rft_id=info:pmid/24585719&rft_oup_id=10.1093/annonc/mdu097&rft_els_id=S092375341934788X&rfr_iscdi=true |